Sweden's ChemoTech Q1 net sales rise, loss narrows on US operation improvement

Scandinavian ChemoTech AB

28/04/2026 07:39

Overview

Sweden medical technology firm's Q1 net sales rose yr/yr, marking its strongest first quarter

Q1 loss after financial items narrowed compared to prior year

Company surpassed 50 installed systems globally during the quarter

Outlook

Company prioritizes expansion in North America and Central Europe through sales staff training

ChemoTech expects recurring revenues from treatment kits to improve predictability and long-term value

Company maintains focus on disciplined execution, operational efficiency, and sustainable growth

Result Drivers

SALES PROCESS IMPROVEMENTS - Co said operational improvements and strengthened sales processes, especially in the U.S., contributed to more reliable revenue generation

ANIMAL CARE ADOPTION - Increased adoption of vetIQure and Tumour Specific Electroporation (TSE) among clinics supported revenue growth

RECURRING REVENUE - Higher share of revenue from recurring treatment kit sales improved predictability and long-term value creation

Company press release: ID:nWkr6Krb9D

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Sales
SEK 2.80 mln
Q1 EPS
-SEK 0.06
Q1 Operating Cash Flow
-SEK 1.14 mln


Analyst Coverage

Wall Street's median 12-month price target for Scandinavian ChemoTech AB is SEK6.30, about 58.7% above its April 27 closing price of SEK3.97

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)